Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NeuroBo completes $24mm Series B round in advance of reverse merge with Gemphire

Executive Summary

NeuroBo Pharmaceuticals Inc. raised $24.24mm in a Series B round that included backing from its existing investor syndicate. The company is merging with Nasdaq-traded Gemphire Therapeutics Inc. after which NeuroBo will own approximately 95.94% of the combined entity and take over Gemphire's public listing. A financing of at least the amount raised was a condition of the merger agreement, and NeuroBo may enter into other subscription agreements for additional proceeds up to a total of $50mm. NeuroBo was jointly founded in July 2017 by JK BioPharma Solutions and Harvard Medical School neurologist Roy Freeman, MD. Its pipeline consists of Phase III NB01 for diabetic neuropathy pain and preclinical NB02 for Alzheimer’s disease, both in-licensed from Dong-A ST in early 2018. The company has raised $41mm to date.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies